Neogenomics (NEO) Operating Leases (2019 - 2026)

Neogenomics has reported Operating Leases for 8 years, with the latest figure at $61.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 2.67% year-over-year to $61.5 million; the trailing twelve-month figure through Mar 2026 stood at $61.5 million (up 2.67% YoY), and the FY2025 full-year result was $62.8 million, up 3.26% from the prior year.
• Operating Leases for Q1 2026 stood at $61.5 million, down from $62.8 million in the prior quarter.
• The five-year high for Operating Leases was $73.4 million in Q1 2022, with the low at $59.9 million in Q1 2025.
• Historically, Operating Leases has averaged $65.5 million across 5 years, with a median of $64.8 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases surged 44.85% — and 2023, when it dropped 12.01%.
• Neogenomics' Operating Leases stood at $69.0 million in 2022, then retreated by 1.57% to $67.9 million in 2023, then decreased by 10.36% to $60.8 million in 2024, then increased by 3.26% to $62.8 million in 2025, then retreated by 2.17% to $61.5 million in 2026.
• The last three Operating Leases figures came in at $61.5 million (Q1 2026), $62.8 million (Q4 2025), and $64.3 million (Q3 2025), per Business Quant data.